CR20210627A - Derivados de benzisoxazol sulfonimada - Google Patents

Derivados de benzisoxazol sulfonimada

Info

Publication number
CR20210627A
CR20210627A CR20210627A CR20210627A CR20210627A CR 20210627 A CR20210627 A CR 20210627A CR 20210627 A CR20210627 A CR 20210627A CR 20210627 A CR20210627 A CR 20210627A CR 20210627 A CR20210627 A CR 20210627A
Authority
CR
Costa Rica
Prior art keywords
compounds
derivatives
benzisoxazole
sulfonimate
patients
Prior art date
Application number
CR20210627A
Other languages
English (en)
Inventor
Ylva Elisabet Bergman Bozikis
Paul Francis Richardson
Samantha Elizabeth Greasley
Robert Arnold Kumpf
Scott Channing Sutton
Oleg Brodsky
Paul Anthony Stupple
Michelle Ang Camerino
Pei-Pei Kung
Robert Louis Hoffman
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Publication of CR20210627A publication Critical patent/CR20210627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona con los compuestos de la fórmula (I), o sales farmacéuticamente aceptables de los mismos, en donde el Anillo A, R1-R8, y n se definen en la presente. Los derivados de benzisoxazol sulfonamida novedosos son útiles para el tratamiento de crecimiento celular anormal, tal como cáncer, en pacientes. Las modalidades adicionales relacionadas con las composiciones farmacéuticas que contienen los compuestos y a métodos de utilización los compuestos y composiciones en el tratamiento de crecimiento celular anormal en pacientes.
CR20210627A 2019-06-18 2020-06-16 Derivados de benzisoxazol sulfonimada CR20210627A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
PCT/IB2020/055589 WO2020254946A1 (en) 2019-06-18 2020-06-16 Benzisoxazole sulfonamide derivatives

Publications (1)

Publication Number Publication Date
CR20210627A true CR20210627A (es) 2022-02-08

Family

ID=71738189

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210627A CR20210627A (es) 2019-06-18 2020-06-16 Derivados de benzisoxazol sulfonimada

Country Status (34)

Country Link
US (3) US11492346B2 (es)
EP (2) EP3986890B9 (es)
JP (2) JP7352662B2 (es)
KR (1) KR102823056B1 (es)
CN (1) CN114364672B (es)
AU (3) AU2020296361A1 (es)
BR (1) BR112021025528A2 (es)
CA (1) CA3143666C (es)
CL (1) CL2021003372A1 (es)
CO (1) CO2021017504A2 (es)
CR (1) CR20210627A (es)
DK (2) DK4299135T3 (es)
EC (1) ECSP21091615A (es)
ES (2) ES2969616T3 (es)
FI (2) FI4299135T3 (es)
HR (2) HRP20231501T1 (es)
HU (1) HUE064683T2 (es)
IL (1) IL288802B2 (es)
LT (2) LT4299135T (es)
MA (1) MA67365B1 (es)
MD (2) MD3986890T3 (es)
MX (1) MX2021016085A (es)
MY (1) MY210207A (es)
PE (1) PE20220808A1 (es)
PH (1) PH12021553107A1 (es)
PL (2) PL3986890T3 (es)
PT (2) PT4299135T (es)
PY (1) PY2027460A (es)
RS (2) RS64931B9 (es)
SI (2) SI4299135T1 (es)
TW (1) TWI787620B (es)
UA (1) UA129891C2 (es)
UY (1) UY38752A (es)
WO (1) WO2020254946A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
US11274082B2 (en) 2019-05-31 2022-03-15 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
PH12021553107A1 (en) 2019-06-18 2022-08-01 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
AU2020295006B2 (en) * 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
US20220024919A1 (en) * 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022187688A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent kras-binding compounds for therapeutic purposes
WO2022187693A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent cdk2-binding compounds for therapeutic purposes
US20240254139A1 (en) * 2021-05-21 2024-08-01 Aurigene Oncology Limited Fused isoxazolyl compounds as kat6a inhibitors
CN118382622A (zh) * 2021-07-05 2024-07-23 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
JP2024529068A (ja) * 2021-08-10 2024-08-01 江蘇恒瑞医薬股▲ふん▼有限公司 スルファミド誘導体、その調製方法及びその医薬的使用
WO2023088233A1 (en) 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
CA3241874A1 (en) 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂
AU2023241822A1 (en) 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
IL317668A (en) * 2022-06-16 2025-02-01 Prelude Therapeutics Inc KAT6-targeted compounds with a ubiquitin ligase-binding residue
US20260027087A1 (en) 2022-07-29 2026-01-29 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
TW202440544A (zh) * 2022-12-20 2024-10-16 中國大陸商杭州中美華東製藥有限公司 具有sting抑制作用的含肟化合物及其藥物組合物和用途
AU2024217108A1 (en) 2023-02-10 2025-09-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of sulfonamide derivative and preparation method therefor
CN120917003A (zh) 2023-03-16 2025-11-07 奥列马制药公司 酰基磺酰胺kat6a抑制剂
WO2024199254A1 (zh) * 2023-03-27 2024-10-03 北京康辰药业股份有限公司 磺酰胺化合物、其药物组合物和应用
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
KR20250172879A (ko) * 2023-04-19 2025-12-09 인실리코 메디신 아이피 리미티드 리신 아세틸트랜스퍼라제 6a (kat6a) 억제제, 그의 조합 및 용도
EP4702019A1 (en) * 2023-04-25 2026-03-04 Insilico Medicine IP Limited Crystalline lysine acetyltransferase 6a (kat6a) inhibitor and uses thereof
WO2025007873A1 (zh) * 2023-07-04 2025-01-09 上海齐鲁制药研究中心有限公司 Kat6抑制剂
AU2024325442A1 (en) * 2023-08-14 2026-03-26 Shanghai Henlius Biologics Co., Ltd. Sulfonamide compound, and preparation method therefor and use thereof
IL327069A (en) * 2023-09-27 2026-05-01 Isosterix Inc Mist inhibitors
WO2025098417A1 (zh) * 2023-11-08 2025-05-15 再和医药科技（苏州）有限公司 磺酰胺类化合物及其应用
WO2025141469A1 (en) 2023-12-26 2025-07-03 Pfizer Inc. Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide
WO2026003716A1 (en) 2024-06-27 2026-01-02 Pfizer Inc. Process for preparing n-(6-((1h-pyrazol-1-yl)methyl)-4-methoxybenzo[d]isoxazol- 3-yl)-2-methoxybenzenesulfonamide
WO2026053122A1 (en) 2024-09-04 2026-03-12 Dana-Farber Cancer Institute, Inc. Methods of treating retinoid responsive cancers
WO2026057050A1 (zh) * 2024-09-14 2026-03-19 北京康辰药业股份有限公司 磺酰胺化合物或其可药用盐的晶型

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (es) 1970-10-08 1974-02-25
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩，およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
FI93954C (fi) 1988-11-29 1995-06-26 Warner Lambert Co Menetelmä lääkeaineina käyttökelpoisten 3,5-di-tert-butyyli-4-hydroksifenyylisubstituoitujen 1,2,4- ja 1,3,4-tiadiatsolien sekä oksadiatsolien ja triatsolien valmistamiseksi
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
JP2902834B2 (ja) 1991-10-09 1999-06-07 本田技研工業株式会社 自己伸縮型マウント
TW224462B (es) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
FI941826A7 (fi) 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ｎｔｎ株式会社 耐熱・潤滑性樹脂組成物
NZ306734A (es) 1995-04-04 2000-01-28 Texas Biotechnology Corp
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
WO1998021186A1 (en) 1996-11-13 1998-05-22 Cephalon, Inc. Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6432994B1 (en) 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
IL160630A0 (en) 2001-11-22 2004-07-25 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
JP2006528193A (ja) 2003-07-22 2006-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼの阻害剤としてのキノリノン誘導体
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
TW200524888A (en) 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
JP2008515980A (ja) 2004-10-12 2008-05-15 デコード ジェネティクス イーエイチエフ 閉塞性動脈疾患のためのアリールスルホンアミドぺリ置換二環式化合物
ES2340066T3 (es) 2005-04-26 2010-05-28 Hypnion, Inc. Compuestos de benzisoxazol piperidina y procedimiento de uso de los mismos.
BRPI0610258A2 (pt) 2005-04-26 2012-09-25 Hypnion Inc composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto
KR20080021030A (ko) 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
BRPI0616872A2 (pt) 2005-10-06 2011-07-05 Sanofi Aventis [1,3,4]-tiadiazol-2il-amidas de ácido aril-sulfÈnico bicìclico, produto farmacêutico compreendendo os mesmos, uso e processo para a preparação do referido produto farmacêutico
RU2008113211A (ru) 2005-10-06 2009-10-10 Санофи-Авентис (Fr) N-[1, 3,4]-тиадиазол-2-илбензолсульфонамиды, способы их получения и их применение в качестве лекарственных средств
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
CA2704336A1 (en) 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
KR20100101165A (ko) 2007-12-26 2010-09-16 사노피-아벤티스 사이클릭 피리딜­ｎ­（１,３,４）­티아디아졸­２­일-벤젠 설폰아미드, 이들의 제조방법 및 약제로서의 이들의 용도
ES2647919T3 (es) 2008-08-13 2017-12-27 Smed-Ta/Td, Llc Implantes de suministro de fármaco
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
WO2010121963A1 (en) 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
AR084370A1 (es) 2009-08-07 2013-05-15 Chugai Pharmaceutical Co Ltd Derivados de aminopirazol
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011085575A1 (zh) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011137089A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
WO2015112465A1 (en) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
AU2015251207B2 (en) 2014-04-23 2019-08-22 Mitsubishi Tanabe Pharma Corporation Novel bicyclic or tricyclic heterocyclic compound
JP5900759B2 (ja) 2014-09-25 2016-04-06 Toto株式会社 小便器
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
PH12021553107A1 (en) 2019-06-18 2022-08-01 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives

Also Published As

Publication number Publication date
EP4299135B1 (en) 2025-08-06
PT4299135T (pt) 2025-10-09
WO2020254946A1 (en) 2020-12-24
US11492346B2 (en) 2022-11-08
EP4299135A2 (en) 2024-01-03
FI3986890T3 (fi) 2024-01-15
CN114364672A (zh) 2022-04-15
MD3986890T3 (ro) 2025-07-31
MD4299135T2 (ro) 2025-11-30
ES3043899T3 (en) 2025-11-26
CN114364672B (zh) 2024-09-06
HRP20231501T1 (hr) 2024-03-01
CA3143666C (en) 2024-06-11
EP4299135A3 (en) 2024-02-28
HUE064683T2 (hu) 2024-04-28
KR20220024671A (ko) 2022-03-03
HRP20251225T1 (hr) 2025-12-05
MA67365B1 (fr) 2025-10-31
DK3986890T3 (da) 2023-12-18
DK4299135T3 (da) 2025-09-08
MX2021016085A (es) 2022-04-20
PT3986890T (pt) 2024-01-17
MD3986890T2 (ro) 2024-04-30
US12371425B2 (en) 2025-07-29
TW202115048A (zh) 2021-04-16
SI4299135T1 (sl) 2025-12-31
UY38752A (es) 2021-01-29
EP3986890A1 (en) 2022-04-27
JP2022537285A (ja) 2022-08-25
AU2023274178A1 (en) 2024-02-15
IL288802A (en) 2022-02-01
CL2021003372A1 (es) 2022-10-07
CO2021017504A2 (es) 2022-01-17
LT3986890T (lt) 2023-12-11
MY210207A (en) 2025-09-03
US20200399258A1 (en) 2020-12-24
PE20220808A1 (es) 2022-05-20
KR102823056B1 (ko) 2025-06-23
LT4299135T (lt) 2025-09-10
PL4299135T3 (pl) 2025-11-12
JP7352662B2 (ja) 2023-09-28
PY2027460A (es) 2021-11-16
RS67276B1 (sr) 2025-10-31
PH12021553107A1 (en) 2022-08-01
RS64931B1 (sr) 2023-12-29
AU2026200976A1 (en) 2026-03-05
AU2020296361A1 (en) 2022-01-06
CA3143666A1 (en) 2020-12-24
US20230174522A1 (en) 2023-06-08
ES2969616T3 (es) 2024-05-21
EP3986890B1 (en) 2023-11-15
ECSP21091615A (es) 2022-01-31
SI3986890T1 (sl) 2024-03-29
JP2023175821A (ja) 2023-12-12
TWI787620B (zh) 2022-12-21
US20260062406A1 (en) 2026-03-05
EP3986890B9 (en) 2025-04-16
FI4299135T3 (fi) 2025-10-01
RS64931B9 (sr) 2025-06-30
PL3986890T3 (pl) 2024-03-11
IL288802B1 (en) 2025-04-01
BR112021025528A2 (pt) 2022-04-19
UA129891C2 (uk) 2025-09-03
IL288802B2 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
PY2005283A (es) Inhibidores de cdk2
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
UY39303A (es) Inhibidores de mutación her2
MX2021015708A (es) Compuestos para el tratamiento de enfermedades de pd-l1.
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
CL2022000956A1 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CO2022015448A2 (es) Compuestos de azalactama como inhibidores de hpk1
DOP2023000281A (es) Inhibidores de mutación de her2
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
AR134005A1 (es) Derivados de benzisoxazol sulfonamida ligados a nitrógeno
PY2153042A (es) Inhibidores de mutación her2
CU20140033A7 (es) Derivados de pirrolopirimidina y purina